135 related articles for article (PubMed ID: 17978568)
1. PPARgamma physiology and pathology in gastrointestinal epithelial cells.
Thompson EA
Mol Cells; 2007 Oct; 24(2):167-76. PubMed ID: 17978568
[TBL] [Abstract][Full Text] [Related]
2. [PPARgamma agonists for the diseases of gastrointestinal tract and liver].
Shimada T; Hiraishi H
Nihon Rinsho; 2010 Feb; 68(2):312-6. PubMed ID: 20158102
[TBL] [Abstract][Full Text] [Related]
3. Peroxisome proliferator-activated receptor-gamma contributes to the inhibitory effects of Embelin on colon carcinogenesis.
Dai Y; Qiao L; Chan KW; Yang M; Ye J; Ma J; Zou B; Gu Q; Wang J; Pang R; Lan HY; Wong BC
Cancer Res; 2009 Jun; 69(11):4776-83. PubMed ID: 19458067
[TBL] [Abstract][Full Text] [Related]
4. 2-cyano-lup-1-en-3-oxo-20-oic acid, a cyano derivative of betulinic acid, activates peroxisome proliferator-activated receptor gamma in colon and pancreatic cancer cells.
Chintharlapalli S; Papineni S; Liu S; Jutooru I; Chadalapaka G; Cho SD; Murthy RS; You Y; Safe S
Carcinogenesis; 2007 Nov; 28(11):2337-46. PubMed ID: 17724373
[TBL] [Abstract][Full Text] [Related]
5. Genetic analysis of peroxisome proliferator-activated receptor gamma1 splice variants in human colorectal cell lines.
Fiatte C; Huin C; Bertin I; Lesuffleur T; Pluvinet A; Touche N; Plénat F; Dauça M; Domenjoud L; Schohn H
Int J Oncol; 2006 Dec; 29(6):1601-10. PubMed ID: 17089002
[TBL] [Abstract][Full Text] [Related]
6. Peroxisome proliferator-activated receptor gamma (PPARgamma) suppresses colonic epithelial cell turnover and colon carcinogenesis through inhibition of the beta-catenin/T cell factor (TCF) pathway.
Fujisawa T; Nakajima A; Fujisawa N; Takahashi H; Ikeda I; Tomimoto A; Yonemitsu K; Nakajima N; Kudo C; Wada K; Kubota N; Terauchi Y; Kadowaki T; Nakagama H; Blumberg RS
J Pharmacol Sci; 2008 Apr; 106(4):627-38. PubMed ID: 18391483
[TBL] [Abstract][Full Text] [Related]
7. Low expression of ORF4, a dominant negative variant of peroxisome proliferator-activated receptor gamma, in colorectal adenocarcinoma.
Bouancheau D; Jarry A; Mottier S; Toquet C; Masson D; Mosnier JF; Laboisse CL; Denis MG
Oncol Rep; 2007 Aug; 18(2):489-95. PubMed ID: 17611675
[TBL] [Abstract][Full Text] [Related]
8. [PPARgamma and cancer].
Nakagama H
Nihon Rinsho; 2010 Feb; 68(2):323-9. PubMed ID: 20158104
[TBL] [Abstract][Full Text] [Related]
9. Peroxisome proliferator-activated receptor gamma pathway targeting in carcinogenesis: implications for chemoprevention.
Ondrey F
Clin Cancer Res; 2009 Jan; 15(1):2-8. PubMed ID: 19118026
[TBL] [Abstract][Full Text] [Related]
10. Peroxisome proliferator-activated receptor gamma overexpression suppresses proliferation of human colon cancer cells.
Tsukahara T; Haniu H
Biochem Biophys Res Commun; 2012 Aug; 424(3):524-9. PubMed ID: 22771328
[TBL] [Abstract][Full Text] [Related]
11. 13-Oxo-ODE is an endogenous ligand for PPARgamma in human colonic epithelial cells.
Altmann R; Hausmann M; Spöttl T; Gruber M; Bull AW; Menzel K; Vogl D; Herfarth H; Schölmerich J; Falk W; Rogler G
Biochem Pharmacol; 2007 Aug; 74(4):612-22. PubMed ID: 17604003
[TBL] [Abstract][Full Text] [Related]
12. PPARgamma as a new therapeutic target in inflammatory bowel diseases.
Dubuquoy L; Rousseaux C; Thuru X; Peyrin-Biroulet L; Romano O; Chavatte P; Chamaillard M; Desreumaux P
Gut; 2006 Sep; 55(9):1341-9. PubMed ID: 16905700
[TBL] [Abstract][Full Text] [Related]
13. Cyclic phosphatidic acid decreases proliferation and survival of colon cancer cells by inhibiting peroxisome proliferator-activated receptor γ.
Tsukahara T; Hanazawa S; Kobayashi T; Iwamoto Y; Murakami-Murofushi K
Prostaglandins Other Lipid Mediat; 2010 Nov; 93(3-4):126-33. PubMed ID: 20932931
[TBL] [Abstract][Full Text] [Related]
14. Herbal isoprenols induce apoptosis in human colon cancer cells through transcriptional activation of PPARgamma.
Au-Yeung KK; Liu PL; Chan C; Wu WY; Lee SS; Ko JK
Cancer Invest; 2008 Aug; 26(7):708-17. PubMed ID: 18608213
[TBL] [Abstract][Full Text] [Related]
15. Disruption of ERalpha signalling pathway by PPARgamma agonists: evidences of PPARgamma-independent events in two hormone-dependent breast cancer cell lines.
Lecomte J; Flament S; Salamone S; Boisbrun M; Mazerbourg S; Chapleur Y; Grillier-Vuissoz I
Breast Cancer Res Treat; 2008 Dec; 112(3):437-51. PubMed ID: 18204896
[TBL] [Abstract][Full Text] [Related]
16. Peroxisome proliferator-activated receptor gamma-independent effects of thiazolidinediones on human cardiac myofibroblast function.
Mughal RS; Warburton P; O'Regan DJ; Ball SG; Turner NA; Porter KE
Clin Exp Pharmacol Physiol; 2009 May; 36(5-6):478-86. PubMed ID: 19673929
[TBL] [Abstract][Full Text] [Related]
17. Genetic and gene expression studies implicate renin and endothelin-1 in edema caused by peroxisome proliferator-activated receptor gamma agonists.
Geese WJ; Achanzar W; Rubin C; Hariharan N; Cheng P; Tomlinson L; Ordway N; Dracopoli NC; Delmonte T; Hui L; Krishnan B; Cosma G; Ranade K
Pharmacogenet Genomics; 2008 Oct; 18(10):903-10. PubMed ID: 18794727
[TBL] [Abstract][Full Text] [Related]
18. Repression of NHE1 expression by PPARgamma activation is a potential new approach for specific inhibition of the growth of tumor cells in vitro and in vivo.
Kumar AP; Quake AL; Chang MK; Zhou T; Lim KS; Singh R; Hewitt RE; Salto-Tellez M; Pervaiz S; Clément MV
Cancer Res; 2009 Nov; 69(22):8636-44. PubMed ID: 19887620
[TBL] [Abstract][Full Text] [Related]
19. PPARgamma agonists attenuate proliferation and modulate Wnt/beta-catenin signalling in melanoma cells.
Smith AG; Beaumont KA; Smit DJ; Thurber AE; Cook AL; Boyle GM; Parsons PG; Sturm RA; Muscat GE
Int J Biochem Cell Biol; 2009 Apr; 41(4):844-52. PubMed ID: 18822385
[TBL] [Abstract][Full Text] [Related]
20. Expression of PPARgamma is reduced by medium supplementation with L-glutamine in human colorectal Caco-2 cells.
Fiatte C; Huin C; Collet P; Plénat F; Dauça M; Schohn H
Int J Mol Med; 2008 Dec; 22(6):825-32. PubMed ID: 19020782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
